Tollys: Raises Over €1.5M from Bpifrance
- Funding consists of 50% non-dilutive funding and 50% long-term loans
- The company will use the funding for the preclinical development of TL-532 in cancer immunotherapy
- In May 2020, Tollys closed a round of financing totaling €2.3m ($2.5M)
- Founded in 2015 by Philippe Guillot-Chêne, chief business officer, and Vincent Charlon, chief executive officer
- Then the company is pioneering TL-532, a new cancer immunotherapy to treat various types of cancer
- Tollys discovered and patented a family of TLR3 agonists and selected TL-532 as its lead-candidate
